Abstract: The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b): enantiomers, diastereomers, salts and solvates thereof wherein R1, R2, R3, R4, R5, and R7 are as defined herein. The invention further includes a method of CCR5-mediated disorders employing such compounds.

Abstract: The invention relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.

Abstract: Disclosed herein are compounds of the formula wherein R1 is independently H or alkyl of 1 to 6 carbons; R2 is optional and is defined as lower alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; n is an integer of between 0 and 2; o is an integer between 0 and 3; R3 is hydrogen, lower alkyl of 1 to 6 carbons, F, Cl, Br or I; R4 is heteroaryl or (R5)p-heteroaryl where the heteroaryl group is 5-membered or 6-membered and has 1 to 3 heteroatoms selected from the group consisting of O, S, and N; p is an integer having the values of 0–5; R5 is F, Cl, Br, I, NO2, N(R8)2, N(R8)CORO8, N(R8)CON(R8)2, OH, OCOR8, OR8, CN, COOH, COOR8, C1-10 alkyl, fluoro substituted C1-10 alkyl, C2-10 alkenyl having 1 to 3 double bonds, C2-10 alkynyl having 1 to 3 triple bonds, or a (trialkyl)silyl or (trialkyl)silyloxy group where the alkyl groups independently have 1 to 6 carbons; A is (CH2)q where q is 0–5, C3-6 branched alkyl,

Abstract: Tert-alkylphenoxy-substituted polycyclic compounds of the general formula I where P is a conjugated polycyclic radical which is stable to bases and nucleophiles, optionally bears aryl substituents and contains no group from the group consisting of —CO—NH—CO—, —COOH and —CO—O—CO—; R is C1–C8-alkyl, whose carbon chain may be interrupted by one or more groups selected from the group consisting of —O—, —S—, —NR1—, —CO— and/or —SO2— and which may be monosubstituted or polysubstituted by C1–C6-alkoxy or by a 5- to 7-membered heterocyclic radical which is attached via a nitrogen atom and may contain further heteroatoms and be aromatic; C5–C8-cycloalkyl whose carbon chain may be interrupted by one or more groups selected from the group consisting of —O—, —S—, —NR1—, —CO— and/or —SO2— and which may be monosubstituted or polysubstituted by C1–C6-alkyl; R1 is hydrogen or C1–C6-alkyl; Hal is chlorine and/or bromine; m is from 0 to 15; n is from 1 to 16, subject to the proviso that the sum m+n is ?16, are prepared a

Abstract: Rylene derivatives of the general formula I where the variables have the following meanings: R is hydrogen or substituted or unsubstituted C1–C30-alkyl, aryl or hetaryl; R1 is hydrogen or bromine; R2 is hydrogen or C1–C6-alkyl; R3 is hydrogen, C1–C18-alkyl or substituted or unsubstituted aryl or hetaryl; and n is 2 or 3.

Abstract: The present invention relates to compounds and more particularly to compounds which are useful for the determination of bicarbonate and the delivery of bicarbonate to a non-aqueous solution. The invention further relates to an optical sensor for the determination of bicarbonate in a liquid sample.

Abstract: The present invention is directed, in part, to fluorescent metal sensors for detecting metal ions, and methods of making and using the same.

Abstract: Rylene dyes of the general formula I where R is hydrogen; unsubstituted or substituted C1-C30-alkyl, aryl or hetaryl; R? is unsubstituted or substituted C2-C30-alkyl or C5-C8-cycloalkyl, or substituted methyl; n is 0 or 1, their preparation and use for coloring high-molecular-weight organic and inorganic materials, and aminorylene-3,4-dicarboximide of the formula IV as their intermediates.

Abstract: In a process for the hydroformylation of ethylenically unsaturated compounds, at least one complex of a metal of transition group VIII. with at least one phosphorus-, arsenic- or antimony-containing compound as ligand is used as hydroformylation catalyst, where the compound used as ligand in each case comprises two groups which comprise a P, As or Sb atom and at least two further hetero atoms and are bound to a xanthene-like molecular framework. New compounds of this type and catalysts which comprise at least one complex of a metal of transition group VIII. with at least one such compound as ligand are also provided.

Abstract: Rylene derivatives of the general formula I where the variables have the following meanings: R is hydrogen or substituted or unsubstituted C1-C30-alkyl, aryl or hetaryl; R1 is hydrogen or bromine; R2 is hydrogen or C1-C6-alkyl; R3 is hydrogen, C1-C18-alkyl or substituted or unsubstituted aryl or hetaryl; and n is 2 or 3.

Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

Abstract: The present invention provides a bleaching composition comprising a [3.3.1] bicyclo compound carrying at least one tertiary amine group the bleaching composition substantially devoid of a peroxygen source.

Abstract: The present invention relates to an organic light emitting diode (OLED) device, comprising an anode disposed on a substrate, an organic EL layer disposed on the anode and a cathode disposed on the organic EL layer.

Abstract: Benzoic acid derivatives useful as intermediates for the preparation of drugs and agricultural chemicals, particularly compounds having herbicidal activity; and easy and economical processes for the preparation of the same. The processes are specifically those represented by reaction formula for the preparation of compounds represented by general formulae (1) and (6).

Abstract: The present invention relates to novel &agr;-substituted-&bgr;-aminoethylphosphonate and &agr;-substituted-&bgr;-aminovinylphosphonate derivatives and their uses for lowering plasma levels of apo (a), Lp(a), apo B, apo B associated lipoproteins (low density lipoproteins and very low density lipoproteins) and for lowering plasma levels of total cholesterol.

Abstract: There are provided novel chemical compounds and their uses in the preparation of polymers and oligomers, and the preparation of such compounds. In certain embodiments there are provided dendritic polymers and oligomers, of a type having at least four polymeric or oligomeric organic chains emanating from a single chemical core, each of the chains being of substantially equal length and substantially the same chemical composition. Such compounds may be referred to as dendrimers. Also provided are novel chemical entities useful as core entities in the preparation of dentrimers. Dendrimers can recognize a core substructure to which the polymeric/oligomeric chains (“dendrons”) are covalenty attached and from which they extend with systematic branching radially outward in a three dimensional fashion, to approximately the same extent to each other. Together, core and dendrons constitute macromolecules possessing a high degree of internal structural replication attributable to the branches.

Abstract: Compounds according to the formula: and pharmaceutically acceptable salts, solvates or hydrates thereof; wherein group Ar is optionally substituted (C6-C10)aryl or (C1-C9)heteroaryl; X is a direct link, —CH2—, —SO2—, —CO—, —CHR1— where R1 is (C1-C6) alkyl, or —CR1′R1″— where both R1′ and R1″ are, independently, (C1-C6)alkyl; Y is N or CH; and Z and W are as herein defined, and pharmaceutical compositions thereof, and methods useful to facilitate secretion of growth hormone(GH) in mammals.

Abstract: The present application describes aryl sulfonyls of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein D, E, and M are defined below, are effective factor Xa inhibitors.

Abstract: The present invention provides formulae for fluorescent compounds that have a number of properties which make them uniquely suited for use in sensors of analytes such as saccharides. The advantageous fluorescent properties include favorable excitation wavelengths, emission wavelengths, fluorescence lifetimes, and photostability. Additional advantageous properties include enhanced aqueous solubility, as well as temperature and pH sensitivity. The compound comprises an aryl or a substituted phenyl botonic acid that acts as a substrate recognition component, a fluorescence switch component, and a fluorophore. Fluorescent compounds are described that are excited at wavelengths greater than 400 nm and emit at wavelengths greater than 450 nm, which is advantageous for optical transmission through skin. The fluorophore is typically selected from transition metal-ligand complexes and thiazine, oxazine, oxazone, or oxazine-one as well as anthracene compounds.

Abstract: The invention relates to compound of formula (I): wherein: G1 represents an alkylene chain as defined in the description, A represents R2 and R3 represent hydrogen, alkyl, alkoxy or hydroxy or together form oxo, R4 and R5 represent hydrogen, R1 is as defined in the description, and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.

Abstract: This invention is directed to functionalized higher diamondoids having at least one functional group.

Abstract: Disclosed are novel aromatic compounds of the formula(I) wherein G, E, W, Ar, X, Y and Z. The compounds are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.

Abstract: Methods for the detection of creatine compound levels in body fluid samples are discussed. Portable kits capable of determining creatine levels using non-invasive and visually detectable methods are also included.

Abstract: The present invention relates to an efficient process for the preparation of 5-(substituted)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinolines.

Abstract: A light emitting device material comprising a compound represented by the following formula (I): wherein R1, R2 and R3, which may be the same or different, each represents an aryl group, a heterocyclic group or an aliphatic hydrocarbon group, provided that at least one of R1, R2 and R3 represents an aryl group or a heterocyclic group, containing a group represented by the following formula (II): wherein R4, R5 and R6, which may be the same or different, each represents a hydrogen atom or a substituent; X1 represents an oxygen atom, a sulfur atom, N—RX1 or CRX2RX3; RX1, RX2, RX3, which may be the same or different, each represents a hydrogen atom or a substituent; R4, R5, R6 and X1 may be linked to each other to form a ring; Y represents an oxygen atom, a sulfur atom, or N—RY1; and RY1 represents a hydrogen atom or a substituent.

Abstract: The invention relates to compounds of formula (I): wherein: G1 represents an alkylene chain as defined in the description, A represents R2 and R3 represent hydrogen, alkyl, alkoxy or hydroxy or together form oxo, R4 and R5 represent hydrogen or together form aryl, R1 is as defined in the description. and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.

Abstract: This invention relates to an improved process for preparing (+) (1S,2R,3S)-3-[2-(2-hydroxyeth-1-yloxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indane-2-carboxylic acid and pharmaceutically acceptable salts thereof, preferably the ethylene diamine 2:1 salt. This invention relates to novel intermediates useful in preparing (+) (1S,2R,3S)-3-[2-(2-hydroxyeth-1-yloxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indane-2-carboxylic acid. This invention relates to an improved process for preparing (+) (1S,2R,3S)-3-(2-carboxymethoxy-4-methoxyphenyl)-1-(3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indane-2-carboxylic acid and pharmaceutically acceptable salts thereof, preferably the disodium salt. This invention relates to novel intermediates useful in preparing (+) (1S,2R,3S)-3-(2-carboxymethoxy-4-methoxyphenyl)-1-(3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indane-2-carboxylic acid.

Abstract: The present invention provides a process for preparing carbocyclic or heterocyclic nitrites by the vapor phase contact ammoxidation of carbocyclic compounds or heterocyclic compounds, in which the reaction is carried out effectively without the increase of the amount of ammonia or oxygen used or the introduction of steam to give the nitrites as the objective products stably with the passage of time in a high yield with a high selectivity.

Abstract: Disclosed are new organometallic complex molecules having light-emitting and electron-transporting characteristics. Also disclosed is organic EL (electroluminescent) devices using these organometallic complex molecules as electron-transporting materials. The organometallic complex molecules are used to form a light-emitting layer with or without doping of another light-emitting material. The organometallic complex molecules can also be used in an electron-transporting layer of the organic EL device. The organic EL devices incorporating the organometallic complex molecules have high thermal stability.

Abstract: The present invention relates to non-psychoactive derivatives of tetrahydro-cannabinol, which exhibit anti-inflammatory, analgesic and leukocyte antiadhesion activities. The invention includes novel derivatives of (3R,4R)-&Dgr;8-tetrahydrocannabinol-11-oic acids [hereinafter referred to as (3R,4R)-&Dgr;8-THC-11-oic acid], as well as pharmaceutical compositions containing the (3R,4R)-&Dgr;8-THC-11-oic acid derivatives. The invention further covers methods of administering the novel derivatives and pharmaceutical compositions as therapeutic agents in the treatment of pain and tissue inflammation. Non-psychoactive derivatives of &Dgr;8-THC-11-oic acid are described which have analgesic and anti-inflammatory properties.

Abstract: An information recording medium is disclosed, comprising a substrate having provided thereon a recording layer capable of recording information by a laser ray, wherein the recording layer contains a dye compound represented by formula (I-1): 1

Abstract: A conductive organopolysiloxane composition is provided which includes (A) 100 parts by weight of an organopolysiloxane; and (B) 0.1 to 800 parts by weight of a conductive material obtained by subjecting a member selected from the group consisting of a conductive metal, a conductive metal compound, a filler surface-treated with a conductive metal and a filler surface-treated with a conductive metal compound, to surface treatment with a compound selected from the group consisting of a compound represented by the formula (1) and a compound represented by the formula (2). ##STR1## wherein R.sup.1 represents --O-- or --NH--, and R.sup.2 represents a hydrogen atom or a phenyl group. This composition is useful for the formation of a silicone rubber having a sufficient electrical conductivity and also stably retainable of electrical conductivity almost without undergoing a change in electrical conductivity even in a high-temperature environment.

Abstract: The present invention provides an indolomorphinan derivative or a pharmacologically acceptable acid addition salt thereof, and an agent for curing and preventing cerebral disorders composed of the derivative and salt thereof, which is represented by the following formula (I): ##STR1## [wherein R.sup.1 represents cyclopropylmethyl or the like; R.sup.2 and R.sup.3 each represent hydroxy methoxy, or the like; R.sup.4 represents hydrogen, methyl, benzyl, 3-isothiocyanatopropyl, or the like; and (R.sup.5).sub.m represents hydrogen, substituted benzo, or the like]. The compounds of the present invention have the excellent effect of preventing damage of the cerebral nerve cells.

Abstract: A process for producing a compound of formula (I): ##STR1## wherein the dotted lines - - - independently represent a single or double bond and R, R.sub.1, R.sub.2 and R.sub.3 are each hydrogen or an organic radical, comprises treating the corresponding 17.beta.-carbonylimidazole intermediates with anhydrous acids in the presence of an amine and, optionally, hydrogenating the resulting compound.

Abstract: An immunogen/vaccine adjuvant composition containing an immunogen in an amount effective to stimulate an immune response and as a vaccine adjuvant a 1H-imidazo[4,5-c]quinolin-4-amine in an amount effective to increase the immune response to the immunogen.

Abstract: A chromogenic receptor comprises a self-assembled chromogenic compound having at least one intrinsic binding site. The chromogenic compound is characterized by the property of producing a reversible color change responsive to binding a target substrate to the receptor. The chromogenic compound has a transition metal ion and at least one ligand bound to the transition metal ion. The ligand is selected from the group consisting of substituted phenanthroline, substituted 2,2'-bipyridine and substituted 2,2':6',2"-terpyridine. The transition metal is selected from the group consisting of Cu(I), Cu(II), Ag(I), Ni(II), Fe(II), Fe(III), Ru(II), Co(III), and Os(II). Self-assembly can be effected in the presence of Cu(I) to form receptors for dicarboxylic acids, carbohydrate, amino acids, steroids and pyrophosphates. The receptors are characterized by the formation of a 2:1 complex of the target substrate with the receptor producing a visible color change from orange to red and a measurable change in its luminescence.

Abstract: Quaterrylenetetracarboxylic diimides I ##STR1## where R is hydrogen;C.sub.1 -C.sub.30 -alkyl whose carbon chain may be interrupted by one or e of --O--, --S--, --NR.sup.1 --, --CO-- and/or --SO.sub.2 -- and which may be monosubstituted or polysubstituted by cyano, C.sub.1 -C.sub.6 -alkoxy or a 5-, 6- or 7-membered heterocyclic radical which is attached via a nitrogen atom and which may contain further heteroatoms and may be aromatic, whereR.sup.1 is hydrogen or C.sub.1 -C.sub.6 -alkyl;C.sub.5 -C.sub.8 -cycloalkyl whose carbon skeleton may be interrupted by one or more of --O--, --S-- and/or --NR.sup.1 --;aryl or hetaryl, which may each be monosubstituted or poly-substituted by C.sub.1 -C.sub.18 -alkyl, C.sub.1 -C.sub.6 -alkoxy, cyano, --CONHR.sup.2, --NHCOR.sup.2 and/or aryl- or hetaryl-azo, which may each be substituted by C.sub.1 -C.sub.10 -alkyl, C.sub.1 -C.sub.6 -alkoxy or cyano, whereR.sup.2 is hydrogen; C.sub.1 -C.sub.18 -alkyl; aryl or hetaryl, which may each be substituted by C.sub.1 -C.sub.

Abstract: Naphthalenelactamimides of the formula I ##STR1## in which, for example, R.sub.1 and R.sub.2 are 2,5-di-tert-butylphenyl and m and n are 0, are novel dyes which have the distinctive features of pronounced fluorescence as a solid and in solvents and a good light-fastness. They are therefore suitable, for example, for mass dyeing of high molecular weight organic material, as laser dyes and for the preparation of printing toners, colour filters, organic photoreceptors, electroluminescent and photoluminescent elements, optical information storage media or solar collectors. The compounds of the the formula I can be prepared by reaction of the corresponding naphthalenetetracarboxylic acid bisimides with a base.

Abstract: This invention relates to methods, reagents, and kits utilizing metal chelates to inactivate nucleotide sequences, especially to inactivate polymerase chain reaction (PCR) and ligase chain reaction (LCR) products and to inactivate nucleotide sequences in a bioprocess and bioproduct. A novel metal chelate class is also disclosed.

Abstract: A compound of the formula (I) or (II): ##STR1## where R.sup.1, R.sup.2, R.sup.5 and R.sup.6 are the same or different and represent a hydrogen atom or a halogen atom and R.sup.1 and R.sup.2 may combine to form a ring; R.sup.3, and R.sup.4 are the same or different and represent a hydrogen atom, a halogen atom, a benzoyl group, a group of the formula --L(CH.sub.2).sub.n R.sup.8 where n is 1 to 8, R.sup.8 is a hydrogen, hydroxy, amino, dialkylamino, --COR.sup.16 or --COOR.sup.14 where R.sup.16 is a hydrogen, chlorine, COCl, C.sub.1 -C.sub.8 alkyl, --NR.sub.2 or aryl and R.sup.14 is a hydrogen, C.sub.1 -C.sub.8 alkyl, aryl, COR, 2,4-dinitrophenyl, N-imido or --NR.sub.2 and L is a direct bond or C.dbd.O; W is .dbd.O; W.sup.1 is hydrogen or --OR.sup.9, where R.sup.9 is hydrogen, C.sub.1 -C.sub.8 alkyl, acyl or a group of the formula --(CH.sub.2).sub.n R.sup.10 where n is 1 to 8 and R.sup.10 is amino, dialkylamino, hydroxy, acryloyl or methacryloyl; Y is oxygen, sulfur, selenium, tellurium, C.dbd.O, or >N--R.

Abstract: The invention provides lanthanide chelates capable of intense luminescence. The celates comprise a lanthanide chelator covalently joined to a coumarin-like or quinolone-like sensitizer. Exemplary sensitzers include 2- or 4-quinolones, 2- or 4-coumarins, or derivatives thereof e.g. carbostyril 124 (7-amino-4-methyl-2-quinolone), coumarin 120 (7-amino-4-methyl-2-coumarin), coumarin 124 (7-amino-4-(trifluoromethyl)-2-coumarin), aminomethyltrimethylpsoralen, etc.The chelates form high affinity complexes with lanthanides, such as terbium or europium, through chelator groups, such as DTPA. The chelates may be coupled to a wide variety of compounds to create specific labels, probes, diagnostic and/or therapeutic reagents, etc. The chelates find particular use in resonance energy transfer between chelate-lanthanide complexes and another luminescent agent, often a fluorescent non-metal based resonance energy acceptor.

Abstract: A pyran derivative has a structure ofR.sup.2 R.sup.3 C.dbd.(C.sub.5 H.sub.2 R.sup.1 O)--(CH.dbd.CH).sub.n --C.sub.6 H.sub.2 R.sup.6 R.sup.7 --NR.sup.4 R.sup.5wherein n is 3 or 4; R.sup.1 is a proton, alkyl or phenyl group; each of R.sup.2 and R.sup.3 is independently a cyano, alkoxycarbonyl having an alkyl, acyl having an alkyl, aracyl having phenyl, sulfonyl, aryl, or aryloxy; each of R.sup.4 and R.sup.5 is an alkyl group; and each of R.sup.6 and R.sup.7 is a proton, provided that R.sup.4 and R.sup.5 are alkyl groups, and a pair of R.sup.4 and R.sup.6 as well as a pair of R.sup.5 and R.sup.7 can be bonded to each other to form a heterocycle.A photosensitive composition comprises a polymerizable compound, a polymerization initiator and a photosensitizer which is the pyran derivative. A photosensitive resin composition comprises a crosslinkable polymer, a crosslinking agent and the photosensitizer.

Abstract: Alkyl aryl sulfones are disclosed which are useful as high temperature and magnetic recording media lubricants. Also disclosed are lubricating mixtures containing the alkyl aryl sulfones, magnetic recording media containing the alkyl aryl sulfones, and a process for lubricating the magnetic recording media with the alkyl aryl sulfones.

Abstract: Provided is an improved process for the synthesis of 1-cyano-3H-dibenz[f,ij] isoquinoline-2,7-dione compounds, and process exhibiting improvements in quality of products, safety, fewer environmental concerns and economics when compared to presently known processes. The compounds are useful as colorants for polyesters, and selected compounds and when combined with small quantities of certain red colorants are particularly efficacious as blue toners for polyesters.

Abstract: A chromophoric molecule capable of forming stable complexes with urea, guanidine or amidine compounds and the acid addition salts thereof which comprises a nucleous of heterocyclic rings.

Abstract: Provided is an improved process for the synthesis of 1-cyano-3H-dibenz[f,ij] isoquinoline-2,7-dione compounds, and process exhibiting improvements in quality of products, safety, fewer environmental concerns and economics when compared to presently known processes. The compounds are useful as colorants for polyesters, and selected compounds and when combined with small quantities of certain red colorants are particularly efficacious as blue toners for polyesters.

Abstract: A molecule capable of forming stable complexes with urea, guanidine or amidine compounds and the acid addition salts thereof comprises a nucleus of heterocyclic rings.

Abstract: A process for the preparation of tertiary N,N-dimethylamines by the reaction of primary amines, formaldehyde, and hydrogen under pressure and at elevated temperature in the presence of a nickel-containing hydrogenation catalyst in the liquid phase. The hydrogenation catalyst is suspended in a solvent, the nickel concentration is 0.1 to 10% by weight, based on the primary amine. The starting materials are separate from each other, brought to 80.degree. to 150.degree. C. and 1 to 15 MPa and fed into the catalyst suspension simultaneously with stirring and reacted in one step to form the tertiary N,N-dimethylamines.

Abstract: Substituted pyrroles of the formula: ##STR1## are disclosed wherein R.sup.1 is (C.sub.1 -C.sub.5)alkyl, C.sub.3 -C.sub.6 (cycloalkyl) alkyl, C.sub.5 -C.sub.7 (cycloalkenyl)alkyl, aryl, aralkyl, trans-(C.sub.4 -C.sub.5) alkenyl, allyl or furan-2-ylalkyl; R.sup.2 is H or OH, R.sup.3 is H, (C.sub.1 -C.sub.5)alkyl or (C.sub.1 -C.sub.5)alkanoyl and R.sup.4 is H or (C.sub.1 -C.sub.5) alkyl; as well as the pharmaceutically-acceptable salts thereof. These compounds are useful as analgesics and/or as selective kappa-opioid antagonists.

Abstract: Orange colors having the anthrapyridine structure ##STR1## are disclosed wherein R.sub.1 and R.sub.2 are independently selected from among hydrogen, halos, lower alkyls, lower alkoxies, nitros, and sulfonates, R.sub.3 and R.sub.4 are independently selected from hydrogens, alkyls and alkylsulfonates of 1 through 3 carbon atoms and R.sub.5 is a lower alkyl or lower alkyl sulfonate.